Objective: To investigate the expression and clinical significance of ribosome-binding protein 1 (RRBP1) in esophageal carcinoma. Methods: A total of 120 esophageal carcinoma patients admitted to Yulin First Hospital of Shaanxi Province from January 2010 to December 2014 were enrolled in this study. RRBP1 expression was detected in esophageal carcinoma and matched adjacent normal tissues by real-time quantitative PCR (qRT-PCR), Western blotting and immunohistochemical staining. The relationships of RRBP1 expression with clinicopathological futures and prognosis were statistically analyzed. Results: RRBP1 expression level was significantly higher in esophageal carcinoma tissues compared with matched adjacent normal tissues. In the mRNA level, the relative quantitative expression in tumor tissues was 3.5±1.3, and 1.0±0.3 in adjacent normal tissues, with a significant difference (t=19.130, P<0.001). In the protein level, the relative quantitative expression in tumor tissues was 1.0±0.4, and 0.3±0.1 in adjacent normal tissues, with a significant difference (t=4.225, P<0.001). The immunohistochemical results showed that RRBP1 high expression was found in 71 (59.2%) tumor tissues, and the proportion dropped to 11.7% (14/120) in adjacent normal tissues, with a significant difference (χ²=59.182, P<0.001). In addition, RRBP1 expression was correlated with lymph node metastasis and TNM stage (χ²=10.631, P=0.001; χ²=31.212, P<0.001). Survival analysis revealed that RRBP1 expression, lymph node metastasis and TNM stage were significantly correlated with patients′ prognosis (χ²=9.455, P=0.006; χ²=14.542, P<0.001; χ²=11.987, P<0.001). Cox regression analysis showed that high expression of RRBP1 (RR=2.441, 95%CI: 1.267-4.702, P=0.008), lymph node metastasis (RR=4.024, 95%CI: 2.180-7.424, P<0.001) and high TNM stage (RR=3.054, 95%CI: 1.452-6.421, P=0.003) were the risk factors for poor prognosis of esophageal carcinoma patients. Conclusion RRBP1 is highly expressed in esophageal carcinoma and can serve as a potential biomarker to predict patients′ prognosis.

Objective To investigate the expressions of forkhead transcription factor O1 (FOXO1) and Kruppel like transcription factor 9 (KLF9) in non-small cell lung cancer (NSCLC) and their clinical significances. Methods A total of 102 patients with NSCLC who underwent surgical resection in the First Hospital of Yulin from September 2012 to June 2015 were selected as NSCLC group, and the paracancerous tissues more than 5 cm far from the edge of the cancer tissues were selected as the control group. The relative expressions of FOXO1 and KLF9 mRNA in NSCLC tissues and paracancerous tissues were detected by real-time quantitative polymerase chain reaction (qRT-PCR), and the immunohistochemistry was used to detect the expressions of FOXO1 and KLF9 in NSCLC tissues and paracancerous tissues. According to the mean mRNA expression in NSCLC tissues, FOXO1 and KLF9 were divided into high expression group and low expression group, their relationships with clinicopathological parameters were observed. The correlation of FOXO1 and KLF9 expressions was analyzed by Pearson method, and the survival of patients was analyzed by Kaplan-Meier method, logistic regression analysis was performed on the related factors affecting the prognosis of NSCLC. Results Compared with the control group, the expression level of FOXO1 in NSCLC group increased (1.28±0.47 vs. 2.82±0.15, t = 31.525, P < 0.05), while the expression level of KLF9 decreased (1.04±0.11 vs. 0.34± 0.07, t = 54.222, P < 0.05). The expressions of FOXO1 were lower in NSCLC tissues of patients with lymph node metastasis, high differentiation, and TNM stage Ⅲ-Ⅳ than those in NSCLC tissues of patients without lymph node metastasis, middle and low differentiation, and TNM stage Ⅰ-Ⅱ, and the differences were statistically significant (all P < 0.05). The expressions of KLF9 were higher in NSCLC tissues of patients with lymph node metastasis, high differentiation, and TNM stage Ⅲ-Ⅳ than those in NSCLC tissues of patients without lymph node metastasis, middle and low differentiation and TNM stage Ⅰ-Ⅱ, and the differences were statistically significant (all P < 0.05). Pearson correlation analysis showed that there was no significant correlation between FOXO1 and KLF9 expression (r = 0.154, P = 0.156). Kaplan-Meier analysis showed that the 3-year overall survival rate of FOXO1 high expression group was lower than that of FOXO1 low expression group (10.81％ vs. 60.71％, χ 2 = 27.341, P < 0.01). The 3-year overall survival rate of KLF9 low expression group was lower than that of KLF9 high expression group (26.32％ vs. 61.54％, χ 2 = 8.526, P = 0.003). Logistic regression analysis showed that FOXO1 was a risk factor for the prognosis of NSCLC (OR = 2.682, P = 0.003), and KLF9 was a protective factor for the prognosis of NSCLC (OR = 0.446, P = 0.012). Conclusions The high expression of FOXO1 and the low expression of KLF9 in NSCLC tissues can be used as effective indexes to predict the progression of NSCLC. The expressions of FOXO1 and KLF9 are closely related to the poor prognosis of patients.